#United States #New York #Securities Law #Pacira BioSciences #PCRX

Legal Cloud Over Pacira BioSciences

On January 20, 2025, The Gross Law Firm alerted shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) about a significant securities law lawsuit filed against the company. This dawn of legal complexities began when shareholders who bought shares between August 2, 2023, and August 8, 2024, were encouraged to reach out for potential participation in this class action lawsuit focused on several allegations surrounding patent integrity.

Details of the Allegations

The crux of the lawsuit stems from a press release issued by Pacira on August 9, 2024. This announcement disclosed adverse findings from a court ruling regarding the validity of its critical patent—U.S. Patent No. 11,033,495, also known as the '495 patent. The court had determined that the patent, which is fundamental for Pacira's main revenue-generating product Exparel, is not valid. This ruling therefore cleared a rival, eVenus, of any patent infringement claims from Pacira, further intensifying the scrutiny on the company’s future profitability.

Exparel accounted for an overwhelming 80% of the company's revenue, making the patent's invalidation a significant blow. Analysts suggest that this could lead to severe repercussions, including potential generic competition entering the market and subsequent litigation costs undermining the company's financial health.

In the wake of this announcement, Pacira's stock price nosedived dramatically from $22.36 per share—a value logged at market close on August 8, 2024—to an alarming low of $11.70 the following day. This plunge reflected an astonishing loss of over 47% in the market value of the company, signaling distress among investors.

Important Deadlines for Investors

As the legal situation unfolds, shareholders face a pivotal deadline for participating in this class action lawsuit. Interested individuals are advised to register their information by March 14, 2025, which marks the last date to initiate a lead plaintiff motion. Furthermore, shareholders who engage will receive ongoing updates and monitoring regarding the case without incurring any fees.

Why Engage with The Gross Law Firm?

The Gross Law Firm specializes in advocating for investor rights and ensuring that corporations are held accountable for misleading practices that impact stock prices artificially. The firm emphasizes that retaining the status of lead plaintiff is not a prerequisite for recovering losses, thus enabling a more inclusive approach for affected investors.

Their commitment is to safeguard the interests of those who have encountered losses due to corporate misinformation or malfeasance. The law firm extends resources for shareholders to navigate this turbulent phase, aiming to restore transparency and justice for investors.

Conclusion

The situation surrounding Pacira BioSciences, Inc. serves as a crucial reminder of the volatility and risks inherent in the investment landscape, particularly concerning biotechnology entities reliant on patent protections for their core offerings. Investors are strongly advised to stay informed and consider taking necessary actions as per the guidance provided by The Gross Law Firm to protect their interests during these uncertain times. For more specifics, potential participants can access the registration link to register for ongoing updates on the class action proceedings.